Recombinant Human Anti-IAV HA Antibody (MAb 3.1) (CAT#: PABL-221)

Recombinant Human Antibody (MAb 3.1) is capable of binding to IAV HA, expressed in HEK 293 cells. Expressed as the combination of a heavy chain (HC) containing VH from anti-IAV HA mAb and CH1-3 region of human IgG1 and a light chain (LC) encoding VL from anti-IAV HA mAb and CL of human kappa light chain. Exists as a disulfide linked dimer of the HC and LC hetero-dimer under non-reducing condition. This antibody potently neutralizes influenza viruses from the H1a clade (i.e., H1, H2, H5, H6) but has little neutralizing activity against the H1b clade.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Datasheet
  • MSDS
  • COA

Figure 1 Figure 1 Neutralizing activity of monomeric 3.1 isotypes. mAb 3.1 IgA1 (red-bordered circles), IgA2 (red circles), IgG1 (black circles), and IgG3 (gray circles) against rg-A/Chicken/Vietnam/C58/2004 (H5N3). Both IgA subtypes neutralized more potently than the IgG subtypes.

Figure 1 Figure 1 Neutralizing activity of monomeric 3.1 isotypes. mAb 3.1 IgA1 (red-bordered circles), IgA2 (red circles), IgG1 (black circles), and IgG3 (gray circles) against rg-A/Chicken/Vietnam/C58/2004 (H5N3). Both IgA subtypes neutralized more potently than the IgG subtypes.

Maurer, M. A., Meyer, L., Bianchi, M., Turner, H. L., Le, N. P., Steck, M.,... & Hangartner, L. (2018). Glycosylation of Human IgA Directly Inhibits Influenza A and Other Sialic-Acid-Binding Viruses. Cell reports, 23(1), 90.

Figure 2 Figure 2 Neutralizing activity of IgG1/IgA1 chimeric 3.1 antibodies.

Figure 2 Figure 2 Neutralizing activity of IgG1/IgA1 chimeric 3.1 antibodies.

The four-letter code refers to the isotype origin of the CH1, hinge, CH2, and CH3, respectively. As a control, 3.1 was included as a pure IgG1 molecule (black closed circles) and an IgA1 molecule (black-bordered open circles) and plotted in each panel. The titration curves of the indicated chimeric molecules are depicted in gray-bordered open circles, while those for IgG1 and IgA1 are depicted in black and white circles, respectively. On top of each panel, the chimerism of the molecule is depicted with IgG1-derived areas in black, IgA1-derived areas in red, and the variable region in white.

Maurer, M. A., Meyer, L., Bianchi, M., Turner, H. L., Le, N. P., Steck, M.,... & Hangartner, L. (2018). Glycosylation of Human IgA Directly Inhibits Influenza A and Other Sialic-Acid-Binding Viruses. Cell reports, 23(1), 90.

Figure 3 Figure 3 Antiviral Effect of Non-specific IgA.

Figure 3 Figure 3 Antiviral Effect of Non-specific IgA.

Left panels: the antiviral activities of HIV-1 gp120- specific mAb b12 and H5-receptor binding sitespecific mAb 65c6 were tested against the indicated viruses. As a control, IgG1, IgA1 expressed in S cells (IgA1 S, red-bordered circles), and samples in which all IgA immunoglobulin has been depleted were used (red triangles). Right panels: antiviral activities of IgG1 or IgA1 of mAbs 3.1, 1.12, and HIV-gp41-specific mAb 2F5 were tested against Newcastle disease virus.

Maurer, M. A., Meyer, L., Bianchi, M., Turner, H. L., Le, N. P., Steck, M.,... & Hangartner, L. (2018). Glycosylation of Human IgA Directly Inhibits Influenza A and Other Sialic-Acid-Binding Viruses. Cell reports, 23(1), 90.


Specifications

  • Immunogen
  • Influenza a virus Hemagglutinin
  • Host Species
  • Human
  • Derivation
  • Human
  • Type
  • IgG
  • Specificity
  • Tested positive against native IAV HA
  • Species Reactivity
  • IAV
  • Clone
  • MAb 3.1
  • Applications
  • Neut, FuncS

Product Property

  • Purity
  • >95% by SDS-PAGE and HPLC analysis
  • Storage
  • Store the antibody (in aliquots) at -20°C. Avoid repeated freezing and thawing of samples.

Applications

  • Application Notes
  • The antibody was validated for Neutralization and Function Assay. For details, refer to Published Data.

Target

  • Alternative Names
  • HA; hemagglutinin; haemagglutinin

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Clone MAb 3.1"

See other products for "HA"

Humanized Antibody

CAT Product Name Application Type
PABX-070-S (P) Recombinant Mouse Anti-HA1 Antibody scFv Fragment (Fab17/9) WB, ELISA, Neut, FuncS scFv

Rabbit Monoclonal Antibody

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for PABL-221. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare